Literature DB >> 7284976

Secretory-component-producing lung cancer with hypergammaglobulinemia of secretory IgA.

T Gotoh, Y Takishita, H Doi, E Tsubura.   

Abstract

Studies were made on a case of well-differentiated adenocarcinoma of the lung in which the serum levels of secretory IgA (sIgA) were very high. Immunofluorescent studies showed that secretory component (SC) was found to be diffusely distributed in cancer cells. The SC was detected in the supernatant of homogenates of cancer tissues from the primary site and lymph node with metastases. The SC extracted from cancer tissue and purified colostral SC were antigenically identical. The authors conclude that the adenocarcinoma cells produced SC and secreted it into the bloodstream and that the binding of SC with polymeric IgA resulted in the hypergammaglobulinemia of sIgA. This appears to be the first reported case of SC-producing lung cancer. The authors' findings suggest that the high serum levels of sIgA in cancer patients may be due to the production and secretion of SC by tumor cells themselves rather than the reabsorption of intraluminal sIgA into the circulation through a damaged epithelium.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7284976     DOI: 10.1002/1097-0142(19811015)48:8<1776::aid-cncr2820480814>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Circulating secretory component in breast neoplasms.

Authors:  D Kvale; T O Rognum; E Thorud; S D Fosså; J S Rø; P Brandtzaeg
Journal:  J Clin Pathol       Date:  1987-06       Impact factor: 3.411

2.  Alterations in polymeric immunoglobulin receptor expression and secretory component levels in bladder carcinoma.

Authors:  M Rossel; C Billerey; H Bittard; P Ksiazek; D Alber; J P Revillard; D A Vuitton
Journal:  Urol Res       Date:  1991

3.  Early detection of liver metastasis in patients with colorectal carcinoma by increased levels of circulating IgA- and IgM-associated secretory component.

Authors:  D Kvale; T O Rognum; P Brandtzaeg
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.